Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Q4 2019/20 Earnings Presentation
31 slides from Bico Group Ab Class B's earnings presentation, Oct 22, 2020
Slide 1: Q4 Earnings call presentation
Q4 Earnings call presentation 2020-10-22
Slide 2: Disclaimer
Introduction Disclaimer You must read the following before continuing. The following applies to this document and the information provided in this presentation by CELLINK AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connect
Slide 3: The future of medicine is here
Introduction The future of medicine is here A unique life-science solution provider Strong momentum since launch Listed on Nasdaq • Net sales amounted to SEK 51,518 thousand (SEK Stockholm (CLNK B) Market cap: SEK ~10.5bn ~330 employees 31,997 thousand), 61% (94%) growth, of which 57% (23%) was orga
Slide 4: The Modern Healthcare Challenges
The Modern Healthcare Challenges High costs and lenghty A life is lost every hour of Animal studies are poor processes for drugs to the day due to lack of indicators of success for reach patients. 9 out of organ transplants human drug development 10 fail in clinical stages! 4 Strictly private and co
Slide 5: The solution is a combination of many solutions
The solution is a combination of many solutions “These challenges obligate health systems and the bio-pharm industry to undergo drastic changes, to identify and develop precise, personalized and effective medical solutions. The attempt to contend with these challenges has given rise to a new multidi
Slide 6: The solution is found in bio-convergence
The solution is found in bio-convergence Drug discovery 3D Cell culturing Regenerative medicine CRISPR & gene editing - tissue printing Diagnostics and Single Cell Omics Bioelectronics Biopharmaceuticals biological sensors 6 Strictly private and confidential
Slide 7: The Bio-Convergence Company
The Bio-Convergence Company CELLINK is creating the future of medicine by providing technologies, products, and services to create, understand, and master biology 7 Strictly private and confidential
Slide 8: Optimized Cell Line Development workflow
Workflows Optimized Cell Line Development workflow Cell Line Development Market ’17-’22 CAGR 8 Strictly private and confidential
Slide 9: Our platform for plate-based single-cell omics workflows
Workflows Our platform for plate-based single-cell omics workflows Single-cell genome sequencing 9 Strictly private and confidential
Slide 10: Fabrication and analysis of tissue models
Workflows Fabrication and analysis of tissue models 10 Strictly private and confidential
Slide 11: Market size
Market size ~$200bn Bioconvergence market opportunity Growth % ~$28bn Bioprocessing Cell Culturing Growth % ~$7bn Single Cell Analysis 3D Cell Culturing Cell Line Development CELLINK Today Note: 1) USD 1.9 billion in 2018 growing at a CAGR of 8.9% over the forecast period between 2018-2023, 2) USD 1
Slide 12: Diversified customer base
Diversified customer base Customer group Main application areas Selected customers % of total sales1) ▪ Human implants (e.g. bone), biomaterials research, cell biology, Single cell ~35% Omics, teaching etc. Universities and ▪ Exploratory research that, if successful, will convert to clinical applica
Slide 13: CELLINK's transformational combination with Scienion
CELLINK’s transformational combination with Scienion creates a global leader in Single Cell handling and precision dispensing 1 Attractive Applications in multiple large, high-growth markets (e.g. single cell handling, liquid handling, array printing, genomics) TAM ~USD5bn5 markets Single cell-dispe
Slide 14: Exciting combined financial profile from Acquisition
Exciting combined financial profile from Acquisition Combined historical revenue development (EURm)1 Comments Cellink net sales based on 2Q LTM for the respective year (e.g. LTM Feb-2020 for 2019A) ▪ Combined growth profile of 57% CAGR over the past three years - Scienon’s strong revenue development
Slide 15: Metrics – Q4
Metrics – Q4 60 MSEK 20,0% 25 MSEK 16,0% 50 MSEK 10,0% 14,0% 20 MSEK 12,0% 40 MSEK 0,0% 10,0% 15 MSEK 30 MSEK -10,0% 8,0% 20 MSEK -20,0% 10 MSEK 6,0% 10 MSEK -30,0% 4,0% 5 MSEK - SEK -40,0% 2,0% - SEK 0,0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 18/19 18/19 18/19 18/19 19/20 19/20 19/20 19/20 Net sales EBITDA % Con
Slide 16: Clear strategy for further growth
Clear strategy for further growth Organic growth initiatives Investment rationale for recent acquisition Continued focus on R&D and innovation to improve customer 1 value proposition by new products and service offering Natural part of the research flow and strong Part of the bioprinting and drug pr
Slide 17: APPENDIX
APPENDIX Strictly private and confidential
Slide 18: Improving Pharmaceutical Workflows
Improving Pharmaceutical Workflows Compound Exploration Assay Development Preclinical Drug 3D Bio- Studies Characterization fabrication Human Clinical Trials Clinical Implementation 2D 3D Strictly private and confidential
Slide 19: The 3D Revolution
The 3D Revolution Embed cells Culture cells in dish Incubate Poor intercellular communication Physiologically relevant Negative influence from substrate More information Grow cells Bioprint Analyze 2D 2D cell sheet Improved models 3D Strictly private and confidential
Slide 20: 3D bioprinting of a corneal stroma equivalent
3D bioprinting of a corneal stroma equivalent Rational design of human tissue with CELLINK https://doi.org/10.1016/j.exer.2018.05.010 Printed into CELLINK Pluronics bed to allow 3D growth Collagen patterns mirrored living tissue Strictly private and confidential
Slide 21: Printing Vascularized Perfusable Skin
Printing Vascularized Perfusable Skin https://doi.org/10.1089/ten.tea.2019.0201 Vasculiarized skin models developed on the BIO X. Leveraged a cooled printhead to print out a novel bioink. Potential to overcome the limitations of graft survival. Strictly private and confidential
Slide 22: Printing Vascularized Perfusable Skin
Printing Vascularized Perfusable Skin https://doi.org/10.1089/ten.tea.2019.0201 © CELLINK 2020, All rights reserved. Strictly private and confidential
Slide 23: Comparing 2D to 3D Cell Culture
Comparing 2D to 3D Cell Culture In house study observed multiple cell types in 2D and 3D to qualitatively demonstrate the benefits of 3D. BIO X™ Vascular cells Stem cells Grow cells Embed cells in bioink Bioprint 3D models Cancer cells Liver cells © CELLINK 2020, All rights reserved. Strictly privat
Slide 24: 3D environment crucial for complex structures and HUVEC networks
A 3D environment is crucial for the development of complex structures and the network formation of HUVECs. Sprouting of HUVECs can only be seen in 3D culture and not in 2D. 2D culture Day 3 3D culture Day 14 GelMA Fibronectin ZO-1 GFP HUVEC DAPI 100 µm ZO-1 GFP HUVEC DAPI 100 µm Strictly private and
Slide 25: Stem cells retain their pluripotency in 3D cultures
Stem cells retain their pluripotency in 3D cultures iPSCs stains for Pluripotency Markers OCT4, SOX2 and NANOG in 3D Cultures after 7 days. 2D2Dculture Day 4 Day 4 3DGelMA culture Day 14 + LN521 GelMA Laminin 521 SOX2 SOX2OCT4 OCT4DAPI DAPI 100 µm SOX2 NANOG DAPI 100 µm 100 µm Strictly private and c
Slide 26: Lung cancer marker in 3D cultures resembles the in vivo like expression
Lung cancer marker in 3D cultures resembles the in vivo like expression Specific Cell Marker β-Catenin Show More Relevant Staining in 3D Models with A549 Lung Adenocarcinoma Cells. 2D culture Day 4 3D culture Day 14 GelMA β-catenin β-catenin 100 µm β-catenin 100 µm Strictly private and confidential
Slide 27: Rearrangement of liver cells to a more organotypic phenotype
Rearrangement of liver cells to a more organotypic phenotype HepG2 Rearrangement and Organotypic Phenotype in 3D culture. 2D2Dculture Day 4 Day 4 3D Collculture 1 Day 14 Coll 1 α-smooth muscle 100 µm α-smooth muscle 100 µm actin actin Strictly private and confidential
Slide 28: Comparing Cancer Drug Efficacy in 2D vs 3D
Comparing Cancer Drug Efficacy in 2D vs 3D Strictly private and confidential
Slide 29: 3D tumor models better recapitulate the tumor microenvironment
3D tumor models better recapitulate the tumor microenvironment. Bioprinting opens the door to improved drug testing workflows. 3D models provide more physiologically relevant interactions and enable longer culture leading to more comprehensive results. BIO X™ I-DOT ™ Harvest Cells: Embed cells in Bi
Slide 30: Avoid false results due to 2D screening
Avoid false results due to 2D screening With improved 3D models like the mini tumors minimize the risk of false positives and negatives. False Positive False Negative BxPC3 BxPC3 CISPLATIN GEFITINIB Strictly private and confidential
Slide 31: Download our Application notes
Want the full picture? Download our Application notes cellink.com/application-notes/ Strictly private and confidential